BROOKE BULLARD: Open Payments
NPI 1871244780 · MIAMI, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,033 in 55 payments from 19 companies in 2025. Trend: 2023 $1,716 · 2024 $2,973 · 2025 $1,033
Food & beverage: $1,033
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $153 |
| AstraZeneca Pharmaceuticals LP | 4 | $136 |
| Alkermes, Inc. | 5 | $114 |
| Novo Nordisk Inc | 5 | $90 |
| ABBVIE INC. | 3 | $64 |
| Lundbeck LLC | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 3 | $49 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
Products named: FANAPT, AIRSUPRA, ARISTADA, REXULTI, CAPLYTA, INVEGA SUSTENNA, Ozempic, VERQUVO.
Industry payments across OK — which companies pay providers there.
